GenomeDx Biosciences today announced that the company has expanded its research agreement with Mayo Clinic to initiate a validation study to expand the use of the Decipher® Prostate Cancer Classifier, a genomic test capable of predicting metastatic prostate cancer, for use in prostate biopsy specimens.
A recent article in Genetic Engineering & Biotechnology News highlights cytogenomic microarray analysis, highlighting Mayo Clinic's communique, “Clinical Utility of Chromosomal Microarray Testing.”
Eric Wieben, Ph.D., director of Mayo’s Medical Genome Facility in Rochester, Minn., discusses how Mayo Clinic is managing big data from personalized medicine in the June issue of CAP TODAY.
In Genetic Engineering & Biotechnology, David Smith, Ph.D., professor of laboratory medicine and pathology at the Mayo Clinic, discusses integrating and interpreting clinical genomics data.
This is the story of two perfectly harmless genes. By themselves, PAX3 and MAML3 don’t cause any problems. However, when they combine during an abnormal but recurring chromosomal mismatch, they can be dangerous. The result is a chimera — a gene that is half of each — and that causes biphenotypic sinonasal sarcoma.
N-of-One, the leading provider of clinical interpretation for precision medicine in oncology, will provide Mayo Clinic access to clinical interpretation information to aid in highly complex molecular diagnostics.
Mayo Clinic and Mayo Medical Laboratories announce the launch of CANCP, a new gene panel cancer test to help tailor therapies to the individual patient based on the unique genomic signature of the patient’s tumor.
This new gene panel cancer test helps tailor therapies to the individual patient based on the unique genomic signature of the patient’s tumor. This test scans specific regions in 50 genes known to affect tumor growth and response to therapies. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.
Piero Rinaldo, M.D., Ph.D., of the Mayo Clinic Biochemical Genetics Laboratory, has been named the 2013 recipient of the prestigious Robert Guthrie Award.
David Murray, M.D., Ph.D., provides a brief overview of the new Alpha-1-Antitrypsin Proteotype S/Z by LC-MS/MS, Serum test now available from Mayo Medical Laboratories. This test should be ordered for individuals suspected of A1A deficiency and can be used for diagnosis and identification of a specific proteotype to determine prognosis.
In part 6 of this 6-part “Hot Topic” series, Piero Rinaldo, M.D., Ph.D., introduces other applications and future developments with the R4S Collaborative Project, that improves detection of true-positives in newborn screening using Mayo-developed software for postanalytical interpretation of complex metabolic profiles.
In Part 5 of this 6-part “Hot Topic” series, Piero Rinaldo, M.D., Ph.D., discusses site-specific customization of post-analytical tools.